Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFER-Fontan trial
2025-524783-38-00Phase 3Authorised
- Sponsor
- UZ Leuven
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of dapagliflozin and spironolactone in Fontan circulation (2 arms), sponsored by UZ Leuven. Primary endpoint: Peripheral venous pressure at rest and peak exercise. Planned start Sep 2026; status: authorised.
02
Drugs
dapagliflozinspironolactone
03
Conditions
Fontan circulation
Beyond the preview
Go deeper on 2025-524783-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524783-38-00.